# Evaluation of IGM-6268 in Healthy Volunteers

> **NCT05160402** · PHASE1 · TERMINATED · sponsor: **IGM Biosciences, Inc.** · enrollment: 54 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** IGM-6268
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05160402
- **Lead sponsor:** IGM Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-07
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-08-18
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2022-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05160402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05160402, "Evaluation of IGM-6268 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05160402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*